Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 90

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 4
Chunk 90
---
Limitations
on Effectiveness of Controls and Procedures

In
designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply
judgment in evaluating the benefits of possible controls and procedures relative to their costs.

8

Evaluation
of Disclosure Controls and Procedures

Our
management, with the participation of our principal executive officer and principal financial officer, evaluated, as of June 30, 2025,
the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based
on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures
were effective at the reasonable assurance level as of June 30, 2025.

Changes
in Internal Control over Financial Reporting

There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.

Part
II. OTHER INFORMATION

Item
1. Legal Proceedings

From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

There
are currently no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims against us or
our property that we believe will have any significant effect on our business, financial position or operating results. None of our officers
or directors is a party against us in any legal proceeding.

Item
1A. Risk Factors

Except
as set forth below in this Item 1A and the Risk Factors included in our previous filings made with the SEC, there have been no material
changes to our risk factors from those disclosed in “Part I. Item 1A. Risk Factors” in the Form 10-K filed with the SEC on
March 13, 2025.

Item
2. Unregistered Sales of Equity Securities and Use